Spyre Therapeutics (SYRE) to Release Quarterly Earnings on Wednesday

Key Points

• Spyre Therapeutics is set to release its Q2 2025 earnings on August 6th, with analysts anticipating an earnings per share loss of ($0.68).
• Institutional investor MIRAE ASSET GLOBAL ETFS HOLDINGS increased its holdings in Spyre Therapeutics by 18.8%, reflecting growing interest in the stock.
• Five research analysts currently rate Spyre Therapeutics with a "buy" recommendation, indicating positive market sentiment, while the stock has a consensus price target of $53.40.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.68) per share for the quarter.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.74) EPS for the quarter, beating analysts' consensus estimates of ($0.76) by $0.02. On average, analysts expect Spyre Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Spyre Therapeutics Stock Performance

NASDAQ:SYRE traded down $0.71 during midday trading on Friday, reaching $16.26. 551,674 shares of the stock traded hands, compared to its average volume of 540,586. The company has a fifty day moving average of $16.19 and a 200 day moving average of $17.14. Spyre Therapeutics has a 12 month low of $10.91 and a 12 month high of $40.26. The stock has a market capitalization of $980.15 million, a P/E ratio of -4.31 and a beta of 2.82.

Analysts Set New Price Targets

A number of equities research analysts recently commented on SYRE shares. Wedbush reiterated an "outperform" rating and set a $65.00 price target on shares of Spyre Therapeutics in a report on Monday, May 5th. Leerink Partners started coverage on shares of Spyre Therapeutics in a report on Tuesday, April 8th. They set an "outperform" rating and a $45.00 price target for the company. Finally, Leerink Partnrs raised shares of Spyre Therapeutics to a "strong-buy" rating in a research report on Tuesday, April 8th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $53.40.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Spyre Therapeutics stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 18.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,018 shares of the company's stock after buying an additional 4,277 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Spyre Therapeutics were worth $442,000 as of its most recent SEC filing. 80.39% of the stock is owned by hedge funds and other institutional investors.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).